



ANTIBIOFILM ACTIVITY OF PROBIOTIC LACTIC ACID BACTERIA FROM COCKROACH (*PERIPLANETA AMERICANA*) GUT

Sana Muneer¹, Sania Naheed² & Ansar Zubair^{3*}

¹ Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore, Pakistan

² Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore, Pakistan

^{3*} Department of Zoology, University of Education, Lahore, Pakistan

***Corresponding author:** Ansar Zubair

*E-mail: Ansarzubair0047@gmail.com

Abstract

This study has been focused on Antibiofilm activity of probiotic lactic acid bacteria from cockroach (*Periplaneta americana*) gut. A total of 20 samples were collected from the cockroach gut isolating bacteria using a 10-fold serial dilution on agar plates incubated anaerobically. Further characterization of the isolated strains included assessing their morphology, Gram staining, and performing various biochemical tests. Isolated strains were evaluated for antimicrobial activity against indicators strains i.e., *E. coli*, *p. aeruginosa*, *s. aureus* and *klebsiella*. Wider zones of inhibition were observed in the case of LAB isolates against *E. coli*, with a range extending from 34mm to 20mm. Among 08 LAB strains 03 were resistant to streptomycin and vancomycin. Probiotic characterization included NaCl, pH, and bile salt tolerance, temperature resistance, auto-aggregation, co-aggregation, and cell surface hydrophobicity. Probiotic strains *Lactobacillus plantarum* CE56.8 and *Lacticaseibacillus rhamnosus* 5974 showed highest growth rate at 8% NaCl concentration. These strains displayed significant growth under various conditions, indicating their potential as probiotics. Importantly, these strains exhibited a notable ability to inhibit biofilm formation by *E. coli* (88%) and *P. aeruginosa* (67%), offer promising effect in combatting biofilm-related infections. explored promising possibilities in the domain of beneficial bacteria, including lactic acid bacteria isolated from the gut of cockroach and lays the foundation for future investigations. However further research is needed to fully understand and develop LAB-based therapeutics for such infections.

Keywords: Cockroach, Lactic acid bacteria, Probiotic, Antibiotic resistance, Biofilm

Introduction

Bacterial resistance is a growing global concern as it refers to bacteria's ability to withstand antibiotics (Church and McKillip, 2021). Bacteria and fungi develop antimicrobial resistance due to self-medication (Dhasarathan et al., 2021). This leads to persistent growth and difficulty in treating infections. The presence of antibiotic resistance results in higher mortality rates, prolonged hospital stays, and also increase healthcare costs. Several factors contribute to drug-resistance among bacteria, including overuse and misuse of antibiotics, serotype substitution, and mutations. According to Rosini et al. (2020), these bacteria can cause hurdle to treat infections. Another significant factor in antibiotic resistance is biofilm formation a structure formed by harmful bacteria. Bacteria in biofilms become resistant to various conditions and substances, including antimicrobial agents, temperature changes,

and the body's defense mechanisms (Clutterbuck et al., 2007). In this scenario, probiotics are a potential solution. Research shows that beneficial bacteria can prevent and treat various illnesses (Sánchez et al., 2017). The idea of restoring a healthy microbiome has led to exploring new therapeutic approaches. Probiotics, including lactic acid bacteria, are known to be helpful (Akova et al., 2021). Using probiotics might reduce the growth and spread of drug-resistant bacteria. The body's natural microbiota, including bacteria, viruses, and fungi play vital role in fighting with pathogens. The microbiota, which exists in large numbers in the human body, helps combat infections by competing harmful bacteria, producing antibiotic substances, and maintaining a strong immune response (MedinaFélix et al., 2023). Combining probiotics with a balanced diet and lifestyle can lower the risk of bacterial resistance and improve overall well-being (Flandroy et al., 2018).

Probiotics are emerging viable microbes used as an alternative to chemotherapeutic agent used to established normal flora and preventing the occurrence of diseases. During infection, they can modulate the immune response, engaging both the innate and adaptive immune systems (Kanauchi et al., 2018). Notably, *Lactobacillus* spp. exhibit exceptional probiotic attributes. When probiotic microorganisms present in sufficient amount within the digestive system, they establish a balance equilibrium between harmful and beneficial gut microbiota (Yadav and Jha, 2019).

Probiotics positively influence host physiology by dietary supplementation with these microbes by increasing immunity, improving nutrition, and encouraging microbial balance in the digestive tract (Reddy et al., 2011).

Lactic Acid Bacteria (LAB) showed probiotic potential and role in limiting the establishment of hazardous organisms have opened up new opportunities in the domains of medical sciences and food biotechnology in recent decades (Raksasiri, 2016). These probiotic LAB strains have made significant contributions in fields of research including physiology, genetics and microbiology. Lactic acid bacteria are Gram-positive, acid-tolerant, non-spore former and can be rod-shaped (bacilli) or spherical (cocci) in shape (Kumar et al., 2022).

Several LAB strains contain proteinaceous bacteriocins that inhibit spoilage and harmful microbes. (Pandey et al., 2013). Lactic acid and other metabolites improve food quality and maintain texture. The use of LAB in the industry has increased due to its GRAS status, which is because of its widespread presence in food and role in maintaining balanced microflora on human and animal surfaces. (Bhogoju and Nahashon, 2022).

Biofilms are populations of bacteria that attach to surfaces and produce a protective framework known as extracellular polymeric substances (EPS) (Mahto et al., 2022). Biofilms can form on various surfaces, including medical devices, and are hard to eradicate with traditional antibiotics. LAB inhibit biofilm development by preventing bacterial adhesion, disrupting the EPS matrix, and entering established biofilms to inhibit growth. LAB produce organic acids, hydrogen peroxide, and bacteriocins, enhancing their effectiveness against biofilm-related illnesses (Giordani et al., 2021).

Biofilms offer a substantial danger in the food industry because they can cause pathogenic and spoilage microorganisms to contaminate food items. Biofilms grow on surfaces and serve as long-term bacterial reservoirs (Schulze et al., 2021). Furthermore, biofilms can serve as reservoirs for pathogens and spoilage bacteria and to survive from cleaning and disinfection treatments. In fact, biofilm-contaminated equipment played a role in 59% of foodborne disease outbreaks evaluated in France (Khelissa et al., 2017).

Biofilms are surface-attached microbial colonies that cause 75% of human microbial illnesses. They have been linked to otitis media, infective endocarditis, atherosclerosis, sialolithiasis, bacterial vaginosis, and mastitis (Bhowmik et al., 2021). Sessile bacteria in biofilms resist stressors like anti-infective drugs. Some microbes with anti-biofilm properties inhibit growth, exclude competitors, and dominate in these competitive communities. (Miquel et al., 2016).

Biofilms play an important role in microorganism survival by supporting the growth, clustering, and maturation of various bacteria and fungi living together (Karygianni et al., 2020). Bacteriocins, unlike

antibiotics, target closely related or identical strains and are produced during primary growth phases through ribosomal peptide synthesis. (Westhoff et al., 2021). Bacteriocins are now frequently used as a natural alternative to synthetic antibiotics, which pose antibiotic resistance in humans and animals, due to their use in foods as biopreservatives and treatments for various disease (Tshibangu-Kabamba and Yamaoka, 2021).

Numerous studies have suggested that cockroach gut microbiota may be developed into effective antibiotic or probiotic for the treatment and prevention of drug-resistant pathogens, potentially offering a solution to the current major public health crisis (Siddiqui et al., 2023).

Cockroach species are associated with human habitats, and some are notorious pests. The insect stomach is important for digesting, food absorption, detoxification, and oxidative stress responses (Zhang et al., 2016). Cockroaches are highly adaptable, but their gut microbiome's potential remains unexplored. This study aims to investigate the therapeutic potential of this microbiome. Specifically, it will examine the antibiofilm effectiveness of lactic acid bacteria with probiotic properties from the American cockroach (*Periplaneta americana*) that may inhibit various infections.

Material and Methods

Sample collection

Cockroaches were collected from residential and commercial settings using trapping techniques and transported to the Zoology lab. Each cockroach's body was cleaned with an alcohol swab to remove contaminants before dissection to expose the gut. One gram of gut tissue was extracted under sterile conditions and placed in a test tube with 9 ml of peptone water, being a nutrient-rich solution, facilitated the growth of microorganisms present in the gut sample. The sample was then mixed thoroughly to disperse microorganisms.



Figure 1. Cockroach gut in Zoology Lab

Serial Dilution & Isolation

A 10-fold serial dilution was prepared by mixing 1 ml of the sample with 9 ml of peptone water. For bacterial isolation, 1 ml of each dilution was spread on MRS agar supplemented with 0.3% CaCO₃ and incubated anaerobically at 37°C for 24 hours. After incubation, distinct colonies were selected, purified through successive streaking, and stored in glycerol stock at -80°C. MRS agar plates enriched with 0.75–1% CaCO₃ were used to identify lactic acid production, where colonies with hollow zones were considered positive for lactic acid.

Characterization of isolated strains

Biochemical test

Biochemical tests are essential for identifying bacterial strains and diagnosing infections by assessing their metabolic and enzymatic activities. Tests like oxidase, catalase, and coagulase identify specific enzymes, while urease, TSIA, and carbohydrate fermentation reveal metabolic pathways. Motility, Methyl Red, Voges-Proskauer, and hemolytic activity tests further distinguish bacteria based on movement, acid production, and red blood cell breakdown, aiding in precise bacterial classification.

Evaluation of the lactic acid bacteria's (LAB) antibacterial potential

The antibiotic activity of LAB strains was evaluated using the Agar well diffusion assay (AWDA)

Agar well diffusion assay (AWDA):

Using the Agar well diffusion experiment, the antibacterial activity of LAB strains against pathogens was assessed. In this procedure, four pathogens (indicators) were spread on the surface of the agar, including *E. coli*, *klebsiella*, *S. aureus*, and *Pseudomonas aeruginosa*. Under aseptic conditions, 6 to 8 mm diameter hole was punched with a sterile puncture and 100ul of the LAB strain supernatant was pour into the well, and incubate for 24 hours.

Antibiotic profile of LAB strains

The selected LAB strains were screened for sensitivity to eight clinically relevant antibiotics: tazobactam, erythromycin, vancomycin, clindamycin, ciprofloxacin, imipenem, streptomycin, and tetracycline, using the Kirby-Bauer Disc diffusion method. The exponentially growing LAB culture was spread on Muller Hinton agar plates (Table 3.3). Place the antibiotic disc separately on the Muller Hinton agar plate and incubate at 37°C for 24 hours. By spreading LAB isolates on Muller Hinton agar, the antibiotic susceptibility of selected strains is screened. Place the disc on the plate and incubate the plate on 37°C for 24 hours. Zone of inhibition was measured in (mm) and designated as sensitive, resistant, and intermediate, followed by the (CLSI) standard.

Determination of probiotic properties of LAB Strains

The probiotic potential of LAB strains was assessed through NaCl, pH, bile salt, and temperature tolerance tests by measuring optical density after incubation. Each test evaluated the growth response of LAB under varying conditions of salt, acidity, bile salt concentration, and temperature.

Auto-aggregation

The strain was incubated for 18 hours at 37°C centrifuged for 4 minutes at 10,000 rpm. The cells were then rinsed twice with phosphate-buffered saline (PBS) and resuspended to a concentration of 10⁸ cfu/mL. 4 mL of the probiotic strain solution was poured separately into sterile tubes and aggressively stirred in order to test the ability to auto-aggregate. 150-µl aliquots of the top suspension were then removed from these test tubes at various time intervals (0, 4, 8, 18, and 24 hours) while they were kept at room temperature without being stirred. A spectrophotometer was used to measure the optical density (OD) at 600 nm. The following equation was used to determine the auto-aggregation percentage:

$$\% \text{ Auto-aggregate} = (A_0 - A_t) / A_0 \times 100$$

Where A₀ is the optical density at time 0, and A_t is the optical density at different time intervals.

CO-aggregation

A sterile test tube was filled with 2 mL of probiotic strain and pathogen culture, and vortexed to assess the co-aggregation. At 0 and 4 hours, aliquots of 150 µL of the suspension were taken, and their absorbance at 600 nm was measured with a spectrophotometer in these tubes at room temperature without stirring, following the method by Pachla et al. (2021). The co-aggregation percentage was calculated as follows:

$$[1 - OD_{\text{mix}} / (OD_{\text{strain}} + OD_{\text{pathogen}}) / 2] \times 100.$$

Where OD_{pathogen} and OD_{strain} are the absorbances of pathogens and LAB at 0 h, respectively, and OD_{mix} is the absorbance of the mixed suspensions at 4 h.

Cell surface hydrophobicity

Shi et al. (2020) developed a modified approach for determining cell surface hydrophobicity. Overnight cultures of LAB strains were centrifuged for 15 minutes at 10,000 rpm and 4°C. The cells

were resuspended in PBS buffer (Table 3.12) after the pellet was washed twice with PBS buffer. The optical density of the cell suspension (OD 600nm) was measured and recorded as A₀. The cell suspension and xylene (a hydrocarbon) were then extensively combined by vortexing. After the mixture had formed two layers, it was incubated at room temperature for 30 minutes. Following that, the aqueous phase was carefully removed, and its absorbance (OD 600nm) was measured again and recorded as A. The following formula was used to determine hydrophobicity:

$$H\% = [(A_0 - A) / A_0] \times 100$$

where A₀ and A represent the absorbances before and after mixing with xylene, respectively.

Antibiofilm activity of probiotics:

Antibiofilm activity was determined using a previously published method that was slightly modified. Fresh sterile tryptone soya broth (TSB) (Table 3.4) was used to grow the pathogenic bacteria overnight. Then, 160 μL of each bacterium's culture was transferred to 96-well microtiter plates. Except for the negative controls, 40 μL of LAB bacterial supernatants were added to each well in order to achieve a final volume of 200 μL. The medium was discarded after 24 hours of incubation at 37 °C. Following that, the biofilms were fixed with 200 μL methanol for 10 minutes, stained with 150 μL 0.1% crystal violet for 10 minutes, and gently rinsed three times with water (Nasr-Eldinet al., 2017). A microplate reader was used to measure the absorbance at 590 nm as the value of biofilm formation. The mean absorbance (OD595 nm) of test organisms was obtained, and the percentage inhibition was calculated using a specific formula.

Percentage inhibition = $100 - ((\text{OD}_{595\text{nm}} \text{ test for positive control well} / \text{OD}_{595\text{nm}} \text{ negative control well}) \times 100)$.

DNA Extraction

The chosen strain's broth culture underwent centrifugation at 10,000 rpm and 4°C. Following this, the supernatant was removed, and the pellet was reconstituted. Subsequently, 400 μL of TE buffer and 100 μL of 10% SDS were gently mixed, followed by the addition of 5 μL of Proteinase K. This mixture was then incubated at 37°C for 1 hour. Next, 500 μL of phenol was added, and the mixture was stirred at room temperature for 4-5 minutes. Afterward, it was centrifuged at 10,000 rpm for 10 minutes. The resulting aqueous supernatant was transferred to a fresh Eppendorf tube for the following steps, while the remaining material was discarded. To this supernatant, 500 μL of either potassium acetate or sodium chloride at pH 5.2 was added, followed by 1 mL of isopropanol. The mixture was then frozen and subjected to centrifugation at 10,000 rpm for 10 minutes. The supernatant was discarded, and the remaining pellet was retained for the next phase. A washing step with 70% ethanol was performed, and the samples were subsequently centrifuged at 5,000 rpm for 5 minutes. Finally, 25 μL of injection water was added to each Eppendorf tube.

Gel-Electrophoresis

Prepare the TAE support solution by transferring 100 mL of buffer into a conical jar. Measure 2 grams of agarose and add it to the 100 mL buffer solution. Keep for a while in the oven. Take from the oven arrangements. Introduce bromide with ethidium into the mixture. For gel casting, pour the resulting solution into the mold and put the pepper. Then, pour the prepared gel solution into the electrophoretic chamber using the 100 mL buffer. In the electrophoretic chamber, carefully position the gel within the caster. Connect the cathodes and activate the system. Following this, power down the supply after 45 to 50 minutes. Remove the gel from the electrophoretic chamber. Place the gel under the UV transilluminator and turn on the transilluminator to examine the results.

16S DNA gene sequencing

To determine the genus of the isolated strain, we conducted DNA sequencing of the 16S ribosomal RNA gene. This sequencing process involved amplifying the specific gene of interest using universal primers designed for 16S ribosomal RNA gene sequencing, which were obtained from:

27F (5'-AGAGTTTGATCCTGGCTCAG-3')

To

1392R (5'GGTTACCTTGTTACGACTT-3')

Results

This study was designed to investigate antibiofilm activity of probiotic lactic acid bacteria from cockroach (*Periplaneta americana*) gut.

Antagonistic activity

Agar well diffusion method

By using the agar well diffusion method against indicator organisms such as *E. coli*, *Klebsiella*, *S. aureus*, and *P. aeruginosa*, the antagonistic potential of isolated strains was assessed. The strains that were examined exhibited varying degrees of antagonistic activity. Table 4.3 shows that 3 out of the 8 strains tested showed significant inhibitory effects against both Gram-positive and Gram-negative indicator strains. The LAB isolates showed wider zones of inhibition against *E. coli*, ranging from 34mm to 20mm (Figure 4.17). In contrast, testing against *Klebsiella* resulted in the lowest zones of inhibition, which ranged from 19mm to 12mm (Figure 4.15).




Figure: Antimicrobial potential of LAB isolates demonstrated through inhibition zones against key pathogenic bacteria: (A) *Pseudomonas aeruginosa*, (B) *Staphylococcus aureus*, (C) *Escherichia coli*, and (D) *Klebsiella* spp. The clear zones around the isolates indicate their effectiveness in combating these harmful microorganisms.

Table 1. Zone of inhibition of isolated strains against pathogens by AWDA

Strain	<i>E. coli</i> mm	<i>Pseudomonas</i> mm	<i>Klebsiella</i> mm	<i>S. aureus</i> Mm
S-1	20	-	12	-
S-2	24	19	9	15
S-3	17	21	-	11
S-4	24	-	10	-
S-5	-	20	-	16
S-6	31	29	11	27
S-7	29	30	19	30
S-8	34	32	12	33

mm= millimeter

Antibiotic profiling of LAB strains

Selected LAB strains showed different response against commonly used antibiotics i.e., tazobactam, erythromycin, vancomycin, clindamycin, ciprofloxacin, imipenem, streptomycin, and tetracycline using Kirby Bauer disc diffusion method. Among 8 LAB strains 03 were resistant to streptomycin and vancomycin 01 strain was only resistant to streptomycin while sensitive to all other antibiotics

Table 2. Antibiotic resistance activity of isolated LAB strains

Sr	Antibiotic disc	S-1 mm	S-2 mm	S-3 mm	S-4 mm	S-5 mm	S-6 mm	S-7 mm	S-8 mm
1	Tazobactam	S	S	S	S	S	S	S	S
2	Ciprofloxacin	S	S	S	S	I	I	S	R
3	Vancomycin	R	R	R	R	R	R	R	R
4	Clindamycin	S	S	R	R	S	S	S	S
5	Erythromycin	S	S	S	S	S	S	S	S
6	Imipenem	S	S	S	S	S	S	S	S
7	Tetracycline	S	I	I	R	S	S	S	S
8	Streptomycin	R	R	R	R	R	R	R	R

LAB strains = S-1, S-2, S-3, S-4, S-5, S-6, S-7, S-8




Figure 2. Comparison of auto-aggregation activity of LAB strains on different time intervals

One-way ANOVA ($p < 0.05$) was used to evaluate the data, followed by the Tukey post hoc test. The results are shown as Mean \pm SEM.

CO-aggregation

Safety testing was performed using a coaggregation assay that was quick, repeatable, and simple to perform. The congregative qualities of two strains with strong auto aggregation capability were examined. co-aggregation was tested of three strains for three pathogenic bacteria (*p. aeruginosa*, *Klebsiella* and *S. aureus*). A considerable degree of coaggregation were seen in strains (S-6 and S-8) for *p. aeruginosa*. Strain S-8 showed highest (51%), S-6 showed (48%) and S-7 showed (38%) against *p. aeruginosa* (Figure 3).




Figure 3. Comparison of Co-aggregation activity of LAB strains

One-way ANOVA ($p < 0.05$) was used to evaluate the data, followed by the Tukey post hoc test. The results are shown as Mean \pm SEM.

Cell surface hydrophobicity

The study used a bacterial adhesion to hydrocarbon assay to evaluate the cell adherence of selected antibiotic-sensitive strains, primarily focusing on their hydrophobic properties. In general, tested isolates exhibited high hydrophobicity (>80%) (Figure 4). Notably, isolates S-6 and S-8 displayed particularly high percentages of cell surface hydrophobicity in the results.




Figure 4. Hydrophobic activity of LAB strains

Antibiofilm activity

In general, *E. coli* and *P. aeruginosa* showed a notable ability to form biofilms. Out of 3 strains isolate S-6 showed 88% antibiofilm activity by *E. coli*, while S-8 resulted in a 70% inhibition (Figure 5). For *P. aeruginosa*, S-6 contributed to a 67% reduction, and S-8 was responsible for a 63% reduction in biofilm formation (Figure 6). These findings highlight the promising potential of LAB strains as probiotics and inhibiting biofilms formed by multidrug-resistant *E. coli* and *P. aeruginosa*.




Figure 5. Comparison of antibiofilm activity of LAB isolates against *E. coli*




Figure 6. Comparison of antibiofilm activity of LAB isolates against *P. aeruginosa*

In this molecular study, LAB strains S6 and S8 were identified using DNA extraction, PCR amplification of the 16S rRNA gene, and gel electrophoresis. The PCR reaction included components such as 2X Master Mix, forward and reverse primers, and template DNA, followed by agarose gel electrophoresis to verify amplification. The 16S RNA genes were purified with the WizPrep™ Gel/PCR Purification Mini Kit (Cat# W70150-300) and sequenced. Sequencing data were analyzed with BioEdit software, and species identification was performed using NCBI BLAST, revealing S6 as *Lactocaseibacillus rhamnosus* (accession number: 5974) and S8 as *Lactobacillus plantarum* (accession number: CE65.8). This comprehensive methodology ensured accurate bacterial species determination.




Figure .Analysisation using Bio Edit software

Discussion

In this section of the investigation, two LAB species, *Lactobacillus plantarum* CE56.8 (S-8) and *Lacticaseibacillus rhamnosus* 5974 (S-6), were selected due to their strong antibiotic activity against pathogens (*E. coli*, *S. aureus*, *Klebsiella*, and *P. aeruginosa*). The probiotic abilities of the isolates were assessed through (a) their ability to withstand varying NaCl, pH, temperature, and bile salt conditions, (b) their adhesion characteristics encompassing biofilm formation, hydrophobicity, and auto-aggregation, (c) their capacity to compete with pathogens via co-aggregation, and (d) a safety evaluation involving their antibiotic susceptibility profile and antimicrobial activity.

One of the desired characteristics of probiotic strains is auto-aggregation, as it helps to inhibit pathogen colonization and lowers the risk of infection (Krausova et al., 2019). After 24 hours of incubation, *Lactobacillus plantarum* CE56.8 (S-8) and *Lacticaseibacillus rhamnosus* 5974 (S-6) displayed the highest levels of auto-aggregation, with >70%.

Based on the results of auto-aggregation assessment, it is possible that *Lactobacillus plantarum* strain CE56.8 (S-8) and *Lacticaseibacillus rhamnosus* strain 5974 (S-6) could form a strong barrier by continuously producing gut biofilm. According to Sannathimmappa et al. in 2021, such a biofilm has the potential to act as an inhibitor against pathogen colonization. These findings are consistent with the findings of Dlamini et al. in 2019, who discovered that *Lactobacillus* isolates have a significant auto-aggregation capacity of 70%.

As defined by Palencia et al. in 2022, Co-aggregation is a form of interaction with pathogens that functions to eliminate these pathogens within the gastrointestinal tract (GIT) and disrupt their capacity to adhere to host tissues. *Lactobacillus plantarum* CE56.8 (S-8) showed highest (51%) and *Lacticaseibacillus rhamnosus* 5974 (S-6) showed (48%) against *p. aeruginosa*. In a recent investigation, According to Shazadi et al. (2002), *L. reuteri*-MT180537 performed best (58%) against *E. faecalis*-MW051601.

Probiotics play a key role in the development of a beneficial biofilm by populating the epithelium, to build a physical barrier to ward off pathogens. Additionally, according to Campana et al. (2017), the ability of LAB strains to maintain their antimicrobial properties over time would seem to be consistent with their ability to adhere to the epithelium. The strains studied were able to producing biofilm, but *Lactobacillus plantarum* strain CE56.8 (S-8) and *Lacticaseibacillus rhamnosus* strain 5974 (S-6) excelled at producing biofilm. This ability allowed them to withstand unfavorable environmental conditions, resulting in successful colonization and population maintenance (Salas-Jara et al., 2016). In a prior investigation, *Lactobacillus fermentum* shown potent biofilm production against *p. aeruginosa* (Shokri et al., 2018)

Probiotics with hydrophobic qualities can greatly improve their host-microbe interaction since mucus, the host's first line of defense, is hydrophobic naturally. Specific cell wall components are supported in their second stage adherence by this primary interaction (Arena et al., 2017). If the H-index is at least 30%–40%, microorganisms can be categorized as hydrophobic; however, microorganisms with an H-index of 10%–15% are not hydrophobic and are unable to adhere to gut mucosa (Shazadi and Arshad, 2022). According to our findings, the two strains with the highest hydrophobicity (>80%) were *Lactobacillus plantarum* strain CE56.8 (S-8) and *Lacticaseibacillus rhamnosus* strain 5974 (S-6). The hydrophobicity tests conducted in this study demonstrate that these strains have strong gut mucosal interactions, which may have an effect on auto-aggregation. The *L. rhamnosus* strain isolated from breast milk exhibits a 69% hydrophobicity to xylene, following previous investigation (Rajoka et al., 2017).

When determining a strain as a potential probiotic, safety assessment in terms of antimicrobial and antibiotic resistance is one of the most significant considerations that must be primarily addressed (Roe et al., 2022). International standards and guidelines (FEEDAP) were used to determine the antibiotic resistance profile (Additives and Feed, 2012). Results showed that all strains were sensitive

to erythromycin and tetracycline and resistant to streptomycin and vancomycin. Lactobacilli isolated from various sources have been found to be resistant to vancomycin and chloramphenicol in a number of investigations (Akpnar Kankaya and Tuncer, 2020).

According to de Melo Pereira et al. (2018), antibacterial activity was the primary goal and an important selection criterion for the identification of innovative and effective probiotics. Pathogenic strains of *E. coli*, *S. aureus*, *P. aeruginosa*, and *Klebsiella* showed antagonistic action against isolated LAB strains from cockroach gut. 07 out of the 8 strains that were identified showed strong to moderate inhibitory zones against *E. coli*. These findings could be attributed to probiotic bacteria, which line the colon and naturally protect it against pathogenic strains. Probiotic bacteria are beneficial to human health. According to earlier research (Ugi Petrovi et al., 2020), LABs displayed varying ZI against *E. coli* that ranged from 12 to 30 mm.

Overall, this research has explored promising possibilities in the domain of beneficial bacteria, including lactic acid bacteria isolated from the gut of cockroach and lays the foundation for future investigations

Conclusion

The investigated LAB strains such as *Lactobacillus plantarum* CE56.8 and *Lacticaseibacillus rhamnosus* 5974 in this study satisfied several requirements for potential use as probiotic microbes. These included the capacity to adhere to hydrocarbons, the ability to auto- and co-aggregate, and a susceptibility to certain antibiotics. Moreover, these strains showed the ability to prevent the growth of biofilms. These results offer hope in addressing antibiotic resistance and improving healthcare outcomes. To fully realize the potential of these probiotics, it is important to conduct clinical trials, assess safety, optimize formulations, and establish regulatory guidelines. These steps will pave the way for the development of effective LAB-based therapeutics for biofilm-related infections, ultimately reducing healthcare costs and enhancing patient care.

References

1. Church, N. A., and McKillip, J. L. (2021). Antibiotic resistance crisis: Challenges and imperatives. *Biologia*, 76(5): 1535-1550.
2. Dhasarathan, P., AlSalhi, M. S., Devanesan, S., Subbiah, J., Ranjitsingh, A., Binsalah, M., and Alfuraydi, A. A. (2021). Drug resistance in *Candida albicans* isolates and related changes in the structural domain of Mdr1 protein. *Journal of Infection and Public Health*, 14(12): 1848-1853.
3. Rosini, R., Nicchi, S., Pizza, M., and Rappuoli, R. (2020). Vaccines against antimicrobial resistance. *Frontiers in immunology*, 11, 1048.
4. Clutterbuck, A., Woods, E., Knottenbelt, D., Clegg, P., Cochrane, C., and Percival, S. (2007).
5. Biofilms and their relevance to veterinary medicine. *Veterinary Microbiology*, 121(1-2): 1-17.
6. Sánchez, B., Delgado, S., Blanco-Míguez, A., Lourenço, A., Gueimonde, M., and Margolles, A. (2017). Probiotics, gut microbiota, and their influence on host health and disease. *Molecular Nutrition and Food Research*, 61(1): 1600240.
7. Akova, B., Kivanç, S., and Kivanç, M. (2021). Antibiofilm effect of probiotic lactic acid bacteria against *Bacillus spp* obtained from the ocular surface. *Eur. Rev. Med. Pharmacol. Sci*, 25, 7799-7805.
8. Medina-Félix, D., Garibay-Valdez, E., Vargas-Albores, F., and Martínez-Porchas, M. (2023). Fish disease and intestinal microbiota: A close and indivisible relationship. *Reviews in Aquaculture*, 15(2): 820-839.
8. Flandroy, L., Poutahidis, T., Berg, G., Clarke, G., Dao, M.-C., Decaestecker, E., Furman, E., Haahtela, T., Massart, S., and Plovier, H. (2018). The impact of human activities and lifestyles on the interlinked microbiota and health of humans and of ecosystems. *Science of the Total Environment*, 627, 1018-1038.
9. Kanauchi, O., Andoh, A., AbuBakar, S., and Yamamoto, N. (2018). Probiotics and paraprobiotics in viral infection: clinical application and effects on the innate and acquired immune systems. *Current Pharmaceutical design*, 24(6): 710-717.

10. Yadav, S., and Jha, R. (2019). Strategies to modulate the intestinal microbiota and their effects on nutrient utilization, performance, and health of poultry. *Journal of Animal Science and Biotechnology*, 10(1): 1-11.
11. Reddy, R. S., Swapna, L., Ramesh, T., Singh, T. R., Vijayalaxmi, N., and Lavanya, R. (2011). Bacteria in oral health-probiotics and prebiotics a review. *Int J Biol Med Res*, 2(4): 1226-1233.
12. Raksasiri, B. V. (2016). Enhancing the efficiency to utilise of inulin from plants as a prebiotics in goat kid diets School of Animal Production Technology Institute of Agricultural Technology, 9, 876.
13. Kumar, M., Nagpal, R., Kumar, R., Hemalatha, R., Verma, V., Kumar, A., Chakraborty, C., Singh, B., Marotta, F., and Jain, S. (2022). Corrigendum to "Cholesterol-Lowering Probiotics as Potential Biotherapeutics for Metabolic Diseases". *Journal of Diabetes Research*, 6, 334.
14. Kumar, V., Chauhan, M., Pophaly, S., Tripathi, A., Kumar, V., Asgar, S., and Agarwal, A. (2022). Preparation of fermented oat drink using lactococcal isolates, 119, 208.
15. Pandey, N., Malik, R., Kaushik, J., and Singroha, G. (2013). Gassericin A: a circular bacteriocin produced by lactic acid bacteria *Lactobacillus gasseri*. *World Journal of Microbiology and Biotechnology*, 29, 1977-1987.
16. Bhogoju, S., and Nahashon, S. (2022). Recent advances in probiotic application in animal health and nutrition: a review. *Agriculture*, 12(2): 304.
17. Mahto, K. U., Priyadarshane, M., Samantaray, D. P., and Das, S. (2022). Bacterial biofilm and extracellular polymeric substances in the treatment of environmental pollutants: Beyond the protective role in survivability. *Journal of Cleaner Production*, 14, 134759.
18. Giordani, B., Parolin, C., and Vitali, B. (2021). Lactobacilli as anti-biofilm strategy in oral infectious diseases: a mini review. *Frontiers in Medical Technology*, 3, 769172.
19. Schulze, A., Mitterer, F., Pombo, J. P., and Schild, S. (2021). Biofilms by bacterial human pathogens: Clinical relevance-development, composition, and regulation-therapeutical strategies. *Microbial Cell*, 8(2): 28.
20. Khelissa, S. O., Abdallah, M., Jama, C., Faille, C., and Chihib, N.-E. (2017). Bacterial contamination and biofilm formation on abiotic surfaces and strategies to overcome their persistence. *J Mater Environ Sci*, 8(9): 3326-3346.
21. Bhowmik, A., Malhotra, A., Jana, S., and Chauhan, A. (2021). Biofilm Formation and Pathogenesis. *Analytical Methodologies for Biofilm Research*, 6, 3-37.
22. Miquel, S., Lagrèfeuille, R., Souweine, B., and Forestier, C. (2016). Anti-biofilm activity as a health issue. *Frontiers in Microbiology*, 7, 592.
23. Karygianni, L., Ren, Z., Koo, H., and Thurnheer, T. (2020). Biofilm matrixome: extracellular components in structured microbial communities. *Trends in Microbiology*, 28(8): 668-681.
24. Westhoff, S., Kloosterman, A. M., van Hoesel, S. F., van Wezel, G. P., and Rozen, D.E. (2021). Competition sensing changes antibiotic production in streptomyces. *MBio*, 12(1): e02729-02720.
25. Tshibangu-Kabamba, E., and Yamaoka, Y. (2021). Helicobacter pylori infection and antibiotic resistance from biology to clinical implications. *Nature Reviews Gastroenterology and Hepatology*, 18(9): 613-629.
26. Siddiqui, R., Elmashak, Y., and Khan, N. A. (2023). Cockroaches: a potential source of novel bioactive molecule (s) for the benefit of human health. *Applied Entomology and Zoology*, 58(1): 1-11.
27. Zhang, J., Zhang, Y., Li, J., Liu, M., and Liu, Z. (2016). Midgut transcriptome of the cockroach *Periplaneta americana* and its microbiota: digestion, detoxification and oxidative stress response. *PloS one*, 11(5): e0155254.
28. Krausova, G., Hyrslova, I., and Hynstova, I. (2019). In vitro evaluation of adhesion capacity, hydrophobicity, and auto-aggregation of newly isolated potential probiotic strains. *Fermentation*, 5(4): 100.
29. Sannathimmappa, M. B., Nambiar, V., and Aravindakshan, R. (2021). Antibiotics at the crossroads—Do we have any therapeutic alternatives to control the emergence and spread of antimicrobial resistance? *Journal of Education and Health Promotion*, 10, 876

31. Dlamini, Z. C., Langa, R. L., Aiyegoro, O. A., and Okoh, A. I. (2019). Safety evaluation and colonisation abilities of four lactic acid bacteria as future probiotics. *Probiotics and Antimicrobial Proteins*, 11(2): 397-402.
32. Palencia, S. L., García, A., and Palencia, M. (2022). Multiple surface interaction mechanisms direct the anchoring, co-aggregation and formation of dual-species biofilm between *Candida albicans* and *Helicobacter pylori*. *Journal of Advanced Research*, 35, 169-185.
33. Shazadi, K., Ahmad, S. Z., Ahmad, S. S., and Arshad, N. (2021). In vivo prophylactic efficacy of *Lactobacillus reuteri* MT180537 against aerobic vaginitis. *Microbial Pathogenesis*, 160, 105197.
34. Campana, R., van Hemert, S., and Baffone, W. (2017). Strain-specific probiotic properties of lactic acid bacteria and their interference with human intestinal pathogens invasion. *Gut pathogens*, 9(1): 1-12.
35. Salas-Jara, M. J., Ilabaca, A., Vega, M., and García, A. (2016). Biofilm forming *Lactobacillus*: new challenges for the development of probiotics. *Microorganisms*, 4(3), 35.
36. Shokri, D., Khorasgani, M. R., Mohkam, M., Fatemi, S. M., Ghasemi, Y., and Taheri-Kafrani, A. (2018). The inhibition effect of lactobacilli against growth and biofilm formation of *Pseudomonas aeruginosa*. *Probiotics and Antimicrobial Proteins*, 10(1): 34-42.
37. Arena, M. P., Capozzi, V., Spano, G., and Fiocco, D. (2017). The potential of lactic acid bacteria to colonize biotic and abiotic surfaces and the investigation of their interactions and mechanisms. *Applied Microbiology and Biotechnology*, 101, 2641-2657.
38. Shazadi, K., and Arshad, N. (2022). Evaluation of inhibitory and probiotic properties of lactic acid bacteria isolated from vaginal microflora. *Folia Microbiologica*, 67(3): 427-445.
39. Rajoka, M. S. R., Mehwish, H. M., Siddiq, M., Haobin, Z., Zhu, J., Yan, L., Shao, D., Xu, X., and Shi, J. (2017). Identification, characterization, and probiotic potential of *Lactobacillus rhamnosus* isolated from human milk. *LWT*, 84, 271-280.
40. Roe, A. L., Boyte, M.-E., Elkins, C. A., Goldman, V. S., Heimbach, J., Madden, E., Oketch-Rabah, H., Sanders, M. E., Sirois, J., and Smith, A. (2022). Considerations for determining safety of probiotics: A USP perspective. *Regulatory Toxicology and Pharmacology*, 9, 105266.
41. Additives, E.P.o., and Feed, P.o.S.u.i. A. (2012). Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary importance. *EFSA Journal*, 10(6): 2740.
42. Akpınar Kankaya, D., and Tuncer, Y. (2020). Antibiotic resistance in vancomycin-resistant lactic acid bacteria (VRLAB) isolated from foods of animal origin. *Journal of Food Processing and Preservation*, 44(6): 14468.
43. de Melo Pereira, G. V., de Oliveira Coelho, B., Júnior, A. I. M., Thomaz-Soccol, V., and Soccol, C. R. (2018). How to select a probiotic? A review and update of methods and criteria. *Biotechnology Advances*, 36(8): 2060-2076.